Navigation Links
Amarantus BioSciences Issues CEO Letter to Shareholders
Date:11/19/2012

SUNNYVALE, Calif., Nov. 19, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that President & CEO Gerald Commissiong issued a letter to shareholders as detailed below.

Dear Shareholders,

I thank you for the trust you have placed in our management team. We fully respect the value of the money you have chosen to invest in Amarantus Biosciences, selecting us over the many other investment options available. We are focused on our mission to offer meaningful products to help patients suffering from debilitating diseases, and we believe our technologies and expertise can have an impact in multiple areas.

As was recently announced, we were able to strengthen the corporation's balance sheet by raising cash and reducing liabilities. These financing transactions were vital for the Company to pay certain vendors who are critical to on-going operations, as well as raise sufficient working capital to pursue our corporate strategy, as detailed below. Our management team and Board of Directors remain extremely dedicated to the overall success of the corporation. This is evidenced by every member working without cash consideration since Amarantus became public in the spring of 2011. This has allowed all available resources to be focused on product development.

With the financing completed, we intend to expand our resources in the areas of corporate communications, regulatory affairs, and product development in order to execute upon our corporate strategy. In this effort, yesterday we received positive feedback at the CNS Summit 2012 on a presentation made by our Chief Scientist. We intend to continue to present the Company at various scientific and investor conferences in order to expose new investor
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amarantus BioSciences Secures $1.1 Million in Financing
2. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
3. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
6. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
7. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
8. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
10. Neurocrine Biosciences Reports Third Quarter 2012 Results
11. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Boston, MA (PRWEB) August 29, 2014 Due ... (FRC) last week, the Adult Stem Cell Technology Center, ... donations to support stem cell therapy research that might benefit ... adult stem cells for new stem cell technologies and therapeutic ... ALS Ice Bucket Challenge donors who wish not ...
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 Best ... products for the food processing industry, is asking industry ... side-by side comparison of the E2 soap they’re currently ... Sanitizing Foam Soap . Hand hygiene is critical ... the food processing environment. Six key criteria are identified ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 “This kit ... test to screen from 0 to 150 ppb,” said Mark ... is a significant benefit to plant owners and USDA-GIPSA inspection ... and other commodities. Testing can take place in a matter ... only can the plant test the feed and grain before ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... Calif., Dec. 12 Codexis, Inc., a leading,developer ... directors have been named to the company,s Board ... Vice President of Innovation and,Chemicals Technology, Shell Global ... Dennis Wolf, Executive Vice President and CFO, MySQL, ...
... PLYMOUTH MEETING, Pa., Dec. 12 Genaera,Corporation (Nasdaq: ... Executive Officer of Genaera, is scheduled to present at ... part of an,RBC Capital Markets, panel discussion of diabetes ... and will take place in,New York on Thursday, December ...
... First Time on 50 mg/Day Dose for PRISTIQ for the ... Treatment of Major Depressive ... of Wyeth (NYSE: WYE ), announces that data from,two ... inhibitor (SNRI), showed,that adult patients who received a 50 mg/day ...
Cached Biology Technology:Rothwell, Wolf Elected to Codexis Board 2Rothwell, Wolf Elected to Codexis Board 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6
(Date:9/1/2014)... animals, bats are perfectly adapted to a life without light. ... reflected echoes to measure distance to obstacles or prey. In ... delays. A study carried out by researchers at Technische Universitt ... map dynamically adapts to external factors. , Closer ... in too close to an object, the number of activated ...
(Date:8/31/2014)... sniffing the highly infectious bacteria C. diff , ... developed by a team at the University of Leicester. ... demonstrated that it is possible to identify the unique ... to rapid diagnosis of the condition., What is more, ... identify different strains of the disease simply from their ...
(Date:8/31/2014)... Change , suggests that if current trends continue ... targets for total greenhouse gas (GHG) emissions in 2050. ... about the food we choose and its environmental impact. A ... of a number of actions that need to be taken ... food for all. , As populations rise and global ...
Breaking Biology News(10 mins):Zooming in for a safe flight 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4
... into a calcium-sensing enzyme already known to play a ... researchers showed that the enzyme, calmodulin kinase II (CaM ... disease called Timothy syndrome and that inhibiting the enzyme ... a new cellular model, could help with developing treatments ...
... Climate change can have significant impacts on high-elevation lakes ... them, according to U.S. Forest Service and University of ... issue of the journal " Herpetological Conservation and Biology ... shallow lakes drying up in summer and predation by ...
... at The University of Queensland could contribute to the ... virus and Dengue fever. Led by Associate ... School of Molecular and Microbial Sciences identified a novel ... belong. The team found all flaviviruses produced ...
Cached Biology News:Rare disease provides clues about enzyme role in arrhythmias 2Rare disease provides clues about enzyme role in arrhythmias 3Climate change effects on imperiled Sierra frog examined 2UQ research targets West Nile virus and dengue fever 2
NORMAL DONOR DONKEY SERUM...
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
B3-1...
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Biology Products: